Standout Papers

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: ... 2021 2026 2022 2024203
  1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study (2021)
    Martin Hutchings, Rogier Mous et al. The Lancet

Citation Impact

1 by Nobel laureates 4 from Science/Nature 62 standout
Sub-graph 1 of 23

Citing Papers

Bispecific T cell engager therapy for refractory rheumatoid arthritis
2024 Standout
A systems view of the vascular endothelium in health and disease
2024 Standout
1 intermediate paper

Works of Rogier Mous being referenced

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
2021 Standout
VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration
2003

Author Peers

Author Genetics PFM Oncology Immunology Last Decade Papers Cites
Rogier Mous 170 296 373 239 35 698
Anna Nosko 13 12 68 266 10 399
B C MacLean 38 689
Deepak Hariharan 1 1 2 11 604
Werner Daum 2 1 20 240
Larry Zhao 23 406

All Works

Loading papers...

Rankless by CCL
2026